Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 448,004 shares of the pharmaceutical company’s stock after selling 5,113 shares during the quarter. Rhumbline Advisers owned 0.18% of Vertex Pharmaceuticals worth $86,348,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bank of The West raised its holdings in Vertex Pharmaceuticals by 6.7% in the 3rd quarter. Bank of The West now owns 9,488 shares of the pharmaceutical company’s stock valued at $1,829,000 after acquiring an additional 596 shares during the last quarter. HPM Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth $252,000. Bain Capital Public Equity Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 168.8% during the 2nd quarter. Bain Capital Public Equity Management LLC now owns 241,408 shares of the pharmaceutical company’s stock worth $41,030,000 after buying an additional 151,614 shares during the last quarter. Senator Investment Group LP increased its holdings in shares of Vertex Pharmaceuticals by 80.2% during the 2nd quarter. Senator Investment Group LP now owns 720,000 shares of the pharmaceutical company’s stock worth $122,371,000 after buying an additional 320,483 shares during the last quarter. Finally, Sun Life Financial INC increased its holdings in shares of Vertex Pharmaceuticals by 266.1% during the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after buying an additional 503 shares during the last quarter. 93.63% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP David Altshuler sold 2,125 shares of the company’s stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $181.89, for a total value of $386,516.25. Following the sale, the executive vice president now owns 41,238 shares in the company, valued at approximately $7,500,779.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Thomas Graney sold 1,076 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $193.24, for a total transaction of $207,926.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 29,550 shares of company stock worth $5,482,235. Company insiders own 0.75% of the company’s stock.

A number of analysts recently weighed in on VRTX shares. BMO Capital Markets upped their price target on shares of Vertex Pharmaceuticals to $204.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. Oppenheimer upped their price target on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. UBS Group upped their price target on shares of Vertex Pharmaceuticals from $183.00 to $188.00 and gave the stock a “neutral” rating in a research report on Thursday, July 26th. Morgan Stanley upped their price target on shares of Vertex Pharmaceuticals from $207.00 to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. Finally, Raymond James set a $201.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 25th. Three equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $202.14.

NASDAQ:VRTX opened at $164.58 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.71 and a quick ratio of 3.59. The stock has a market capitalization of $44.17 billion, a price-to-earnings ratio of 205.73, a PEG ratio of 1.72 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 1-year low of $136.50 and a 1-year high of $194.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.07. The company had revenue of $784.54 million during the quarter, compared to analysts’ expectations of $782.95 million. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. During the same period in the prior year, the company posted $0.53 EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/15/vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-rhumbline-advisers.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: What is the Rule of 72?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply